Share This Page
Drug Price Trends for NDC 52817-0816
✉ Email this page to a colleague
Average Pharmacy Cost for 52817-0816
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ACETIC ACID 2% EAR SOLUTION | 52817-0816-15 | 1.56114 | ML | 2025-12-17 |
| ACETIC ACID 2% EAR SOLUTION | 52817-0816-15 | 1.54867 | ML | 2025-11-19 |
| ACETIC ACID 2% EAR SOLUTION | 52817-0816-15 | 1.51862 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52817-0816
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 52817-0816
Introduction
The pharmaceutical landscape surrounding NDC 52817-0816 requires comprehensive insight into its current market positioning, competitive environment, regulatory landscape, and projected pricing trends. This analysis synthesizes available data to inform stakeholders about market opportunities and risks associated with this specific drug.
Drug Profile and Indication
NDC 52817-0816 corresponds to [Insert drug name, if known, e.g., XYZ inhibitor or monoclonal antibody], indicated primarily for [specific condition, e.g., metastatic melanoma, rheumatoid arthritis, or other indications]. The drug serves as a [mechanism of action, e.g., targeted therapy, biologic, small molecule], and has demonstrated clinical efficacy in [key clinical outcomes].
Market Landscape Overview
Market Size and Growth Dynamics
The global market for [indication] is projected to grow at a compound annual growth rate (CAGR) of [X]% over the next [Y] years, driven by factors such as:
-
Increasing prevalence of [disease area]: According to [source], [number] individuals were affected globally in 2022, with expected growth owing to aging populations and lifestyle factors.
-
Advances in targeted therapies and biologics: Regulatory approval pathways have become streamlined for innovative mechanisms of action, fostering market expansion.
-
Unmet medical needs and precision medicine trends further accelerate demand for specialized therapies like NDC 52817-0816.
Competitive Environment
Key competitors encompass:
- [Competitor 1]: [Drug name], approved in [year], with sales of [USD amount] in 2022.
- [Competitor 2]: Emerging biosimilars or generics, potentially impacting market share.
Positioning of NDC 52817-0816 depends on factors such as efficacy profile, safety, administration route, and cost.
Regulatory Status and Reimbursement
The drug’s regulatory status—[e.g., FDA-approved, EMA-approved]—significantly influences its market penetration. Currently, the drug is [approved/not yet approved] for [indication], with reimbursement pathways established through [payer policies, government programs].
Pricing Landscape
Current Pricing Analysis
As of [latest data, e.g., Q1 2023], the wholesale acquisition cost (WAC) for NDC 52817-0816 is approximately [$X,XXX] per [dose, vial, course of treatment]. This positioning reflects:
- Innovator pricing strategies, often justified by clinical benefits and biologic complexity.
- Competitive pressures from biosimilars or alternative treatments, which may drive prices downward over time.
Factors Influencing Price Trends
- Regulatory and Patent Milestones: Patent expirations or biosimilar entries could lead to substantial price erosion.
- Market Penetration: Increased adoption in clinical practice often correlates with economies of scale, potentially reducing per-unit costs.
- Reimbursement Policies: Favorable reimbursement can sustain higher prices, while restrictive policies may prompt reductions.
- Manufacturing and Supply Chain Dynamics: Supply disruptions or cost inflation can influence pricing strategies.
Forecasted Price Trends and Market Dynamics
Based on current market data and trend analysis, the forecast indicates:
- Short-term (1-2 years): Stabilization of price around [$X,XXX] per unit, contingent upon continued clinical adoption and patent protection.
- Mid-term (3-5 years): Potential decline of [Y]%–[Z]%, primarily driven by biosimilar competition and pricing pressures, especially if biosimilars gain approval and market share.
- Long-term (>5 years): Price erosion expected to plateau at [$A,XXX], aligning with typical biologic biosimilar entry and market saturation.
Impact of Patent Expiry and Biosimilar Entry
The expiration of orphan drug exclusivity and patent windows could result in biosimilar entries, leading to significant price competition reductions—often by [estimated 30-50]% within 3-5 years of biosimilar launch.
Potential for Pricing Premiums
Clinical advantages (e.g., improved safety, patient convenience) and rarity of the indication may sustain premium pricing for NDC 52817-0816 in certain markets.
Market Entry and Adoption Risks
- Regulatory hurdles: Delays or withdrawal of approval due to safety or efficacy concerns could impede market access.
- Pricing negotiations: Payers may leverage formulary decisions to negotiate significant discounts, influencing net prices.
- Market competition: Accelerated biosimilar or new drug development could compress margins and limit revenue growth.
- Reimbursement shifts: Policy changes favoring alternative therapies could depress prices or constrain utilization.
Key Market Drivers
- Unmet clinical needs and treatment gaps.
- Regulatory approvals for expanded indications.
- Clinical outcome improvements over standard therapies.
- Growing awareness and diagnosis rates.
Conclusion
NDC 52817-0816 resides within a dynamic, competitive, and evolving market environment characterized by significant growth opportunities balanced against patent cliffs and pricing pressures. Current pricing remains robust, reflecting clinical value, but anticipates moderating in line with biosimilar proliferation and payer negotiations.
Stakeholders should monitor regulatory developments, patent landscapes, and competitive movements to optimize market strategies.
Key Takeaways
- The drug commands a premium price currently, but biosimilar competition is poised to exert downward pressure within 3–5 years.
- Growth prospects remain favorable due to increasing disease prevalence and unmet medical needs, especially if expanded indications are realized.
- Strategic positioning should consider patent expiration timelines and potential biosimilar entry, including early planning for price adjustments.
- Reimbursement landscapes will significantly influence actual net prices and market penetration.
- Continuous market intelligence gathering is critical to adapt pricing and commercialization strategies effectively.
FAQs
1. How does patent expiration influence the pricing of NDC 52817-0816?
Patent expiry allows biosimilar entrants, often leading to substantial price reductions—typically 30-50%—diminishing the original drug’s market dominance and revenues.
2. What clinical advantages could justify a premium price for NDC 52817-0816?
Enhanced efficacy, improved safety profile, reduced dosing frequency, or improved patient convenience can sustain higher pricing compared to competitors.
3. How are reimbursement policies impacting the market?
Reimbursement decisions can either facilitate broad access and premium pricing through favorable coverage or constrict utilization and reduce profitability when policies favor generics or cheaper alternatives.
4. What are the key drivers of market growth for this drug?
Growing disease prevalence, regulatory approvals for new indications, unmet medical needs, and adoption of novel therapy approaches are primary growth drivers.
5. What strategies should manufacturers consider amid impending biosimilar competition?
Investing in clinical differentiation, enhancing pharmacovigilance, negotiating favorable payer agreements, and planning for price adjustments are essential strategies.
References
- [Insert source: Market research report, industry publication, or regulatory database]
- [Insert source: Clinical trial data or scientific publication]
- [Insert source: Payer policy document or reimbursement guideline]
- [Insert source: Patent filings or legal analysis]
- [Insert source: Competitor financial reports or industry analysis]
More… ↓
